Investing
Regeneron beats quarterly profit estimates
© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo
(Reuters) – Regeneron Pharmaceuticals Inc (NASDAQ:) beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.
Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts’ estimates of $9.56, according to Refinitiv data.
(This story has been corrected to remove reference to Eylea in the headline and paragraph 1)
Read the full article here